Binx Health Inc.

Founded in 2005 and based in Massachusetts, US, Binx Health Inc. , formerly Atlas Genetics, operates as a diagnostics company developing ultra-rapid point-of-care tests for infectious diseases. John Clarkson and Pavel Rodyukov are the co-founders of the company. The firm has grown through various fundraising starting with an unspecified round (2006), Series A (2008), grant (2009) Series B (2014), Series C (2015), Series D (2017), and another unspecified round in 2020.

In May 2021, the firm raised USD 104 million in Series E funding led by OrbiMed Advisors including Alta Life Sciences, ArrowMark Partners, Hildred Capital Partners, and Parian Global Management. Further in December 2023, Binx Health Inc. was acquired by Imaware, Inc. , from Alta Life Sciences, ArrowMark Partners, EQT Life Sciences, Hildred Capital Partners, etc.

The Company’s binx io is a first-of-its-kind FDA-cleared, CLIA-waived, highly sensitive and specific, point-of-care (POC) diagnostic testing platform and is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)–the two most notifiable STI conditions. Binx Health's solutions are designed to break down screening barriers through discreet patient-tailored digital approaches that complement traditional brick-and-mortar care. In addition to binx io, the organization offers a comprehensive digital program that includes access to evidence-based testing, counseling, treatment, and follow-up aimed at increasing testing and reducing infection spread.